Member Info for Matml74

They aren't all sells as they are being marked as buy/sell when compared against todays closing spread (182/183). Only way you can work them out is look at Fridays spreads against the times they were printed.

I am sure this has been said many times but ignore the buy/sell tag the LSE puts against the trades., they are generally wrong!

I went through all todays trades and corrected against spreads.

Total volume sells today 800k
Total volume buys 910k

Only thing out of the ordinary today the two largest trades of the day were a 200k sell and an 87k sell but they were traded at a price of 175.144 and 175.175 respectively when the spread was 180/183. Neither were delayed either. Strange.

Don’t think we will see these until after the general meeting.

Hopeful, 120 patients in the home trial.

I agree Doc hat millions are saved by vaccination. There was no implication by me that these deaths occurred in people taking a vaccine or not. Not sure why you would think that.

It is just a simple fact. Vaccine or not, treatment’s are needed for all of those who can’t (either by choice or personal circumstance) have access to a vaccine.

Really Org? I have not seen that and I watch the price pretty closely. Since September at least I feel it has been moved around mainly by plays in the background relating to the placement and I buying. If it drops tomorrow it’s probably more related to the downward trend towards placing price than anything else.

WHO reported that between 300,000 and 790,000 people died of flu in 2019. Surprise, surprise a flu vaccine exists!...... There will always be a need for treatment.

If this drug gets through phase 3 trials there is going to be a market for it worldwide for many years to come. It is that simple!

Burn it’s not 100. This research has been done in asthma trials and copd and found the same response. Look a bit deeper!

Bamp, I have been involved in a fair number of papers that went for peer review and none were done insider 6 months. Obviously this is a different situation but for peer review all the data has to be reanalysed. It is not something that happens quickly as generally the reviewers have their own work they are undertaking and I suspect in this case it will also be revolving around covid. The peer review will not make any difference to the approval process.

If the FDA thought the data was rubbish we wouldn’t be doing a phase 3. This whole peer review thing was bought up by the journalists at the July 20 press conference and seems to have stuck.

Green label, not sure but they are the drivers behind this placement.

I will be taking up the open offer because the funds will go directly to Synairgen to complete this work. I could hold out and hope for a lower buy in but would rather the company had the money.

JBER have been doing this since the days of being in the 30’s!! WHATS thier issue with us!

NUMIS has been proping up the bid daily since the placement.

Al, I believe the term ‘randomised’ just relates to the fact that patients are assigned the drug or placebo by chance, not whether the trial is blinded or not.

As you say all will be revealed soon though.

When you see the huge amounts being thrown at testing devices (and some pretty small and obscure companies at that!) by this government the funds to hugely scale up production with multiple suppliers could be achieved in a very short space of time if phase continues to provide proof of efficacy.

Thats how I see it Doc.

Al,

What do you see different in these two statements.

"Synairgen's Phase II trial in COVID-19 patients (SG016) will be a double-blind, placebo-controlled trial. "

"Synairgen intends to commence a Phase III randomised placebo-controlled trial of SNG001 in hospitalised COVID-19 patients, named SG018, with an anticipated start date during Q4 2020".

Says to me it's not double blinded. Should be clearly stated if it is. The FDA have advised what is required and ticked off the protocol. They already have 'gold standard' data from the phase 2. If the ratios of death's in the placebo vs SNG001 group continued the phase 3 then there would be another 30 odd people dying for no reason.

Yes Robert. The patient doesn't know whether they are receiving placebo or SNG001 but the clinician does. More likely to share with regulators to get EUA.

I agree Manifesto. If the phase 3 is clearly showing a benefit then EUA should come before trial end, particularly with the FDA heavily involved.

"The FDA has provided Synairgen with guidance on the Phase III clinical study to support the potential registration of SNG001 for the treatment of COVID-19."

Robert,

The trial is not double blind.

Bapuk, Well said. POC is the future of testing. This is great news for the company and to be fair I wasn't expecting to see this development for another few months. Product launch next qrt will see plenty of sales.

Agree Red. People also seem to forget the following.

It worked in the LAB
It worked in ASTHMA trial
It worked in COPD trial
It worked in COVID trial

It works.

Let all these shenanigans pass and Be patient.

Looks like it Kmac.